J&J Unit's Stelara Infringes Abbott Patents, Judge Rules

Law360, New York (March 12, 2012, 3:19 PM EDT) -- A Massachusetts federal judge ruled Friday on several competing summary judgment bids in a legal battle between Abbott GmbH & Co. KG and Johnson & Johnson unit Janssen Biotech Inc., finding that Janssen's psoriasis treatment Stelara infringes two human antibody patents.

In addition to partially granting Abbott's motion for summary judgment of infringement, U.S. District Judge F. Dennis Saylor IV also shot down defendants Centocor Ortho Biotech Inc. and Centocor Biologics Inc.'s bid for a ruling that Stelara did not infringe any of the asserted claims....
To view the full article, register now.